Toxoid Antigen Presentation and Germinal Center Antitoxin IgG Maturation
trigger
Chemical detoxification (classically with formalin and heat) or genetic inactivation abolishes the enzymatic and cytopathic toxicity of secreted bacterial exotoxins while preserving native conformational epitopes. Intramuscular immunization with adjuvanted toxoid primes CD4+ T-cell-dependent germinal center reactions that generate long-lived plasma cells and memory B cells secreting high-affinity toxin-specific IgG antibodies.
Downstream
-
Bacterial AB Exotoxin Host Receptor Binding and Cellular Intoxication
Circulating antitoxin IgG antibodies target the receptor-binding and translocation steps of secreted bacterial AB exotoxins
Show evidence (2 references)
"In 1923 began the era of human toxoid vaccination, after Gaston Ramon demonstrated that formalin combined with heat eliminated the toxicity of the diphtheria toxin without altering its antigenicity or immunogenicity, thus introducing the anatoxin (generally called toxoid) principle."
Establishes the foundational toxoid principle whereby formalin inactivation eliminates exotoxin toxicity while preserving immunogenicity.
"In the 1940s, diphtheria toxoid, tetanus toxoid and pertussis antigens were combined in the diphtheria-tetanus-pertussis vaccine, still used widely throughout the world."
Documents the conserved clinical deployment of combined diphtheria, tetanus, and pertussis toxoid antigens to elicit systemic antitoxin immunity.
Bacterial AB Exotoxin Host Receptor Binding and Cellular Intoxication
therapeutic vulnerability
Secreted bacterial AB-type exotoxins (including diphtheria toxin, tetanus neurotoxin, and pertussis toxin) bind specific host cell-surface receptors via their B (receptor-binding) domain, undergo receptor-mediated endocytosis, and translocate their catalytic A subunit into the host cytosol to modify intracellular targets (such as eEF2, SNARE proteins, or Gi alpha subunits). This extracellular receptor-engagement and internalization step is the canonical conformance and therapeutic target of toxoid vaccines and passive antitoxins: conforming disorder entries align their primary exotoxin action node here, and toxoid vaccine treatments direct their inhibitory target_mechanisms edge at that conforming node.
Used by disorders
Diphtheria
as Diphtheria Toxin Binding to the proHB-EGF Receptor
Pertussis
as Pertussis Toxin-Mediated Disruption of Host Gi Signaling
Tetanus
as Tetanus Toxin (Tetanospasmin) Action
Downstream
-
Neutralizing Antitoxin IgG Blockade of Exotoxin Receptor Binding
When bound by toxoid-induced or passively administered neutralizing IgG antitoxin in blood and interstitial fluid, the exotoxin is sterically prevented from engaging host receptors
Show evidence (2 references)
"We further established that our lead candidate hMAb binds to the receptor-binding domain of diphtheria toxin and physically blocks the toxin from binding to the putative receptor, heparin-binding epidermal growth factor-like growth factor."
Identifies the exotoxin receptor-binding step (diphtheria toxin binding to proHB-EGF) that is required for cellular intoxication and targeted by neutralizing antitoxin antibodies.
"Tetanus and botulinum neurotoxins cause the neuroparalytic syndromes of tetanus and botulism, respectively, by delivering inside different types of neurons, metalloproteases specifically cleaving the SNARE proteins that are essential for the release of neurotransmitters."
Establishes receptor-mediated neuronal delivery and intracellular enzymatic target cleavage as the conserved pathogenic mechanism of bacterial neurotoxins.
Neutralizing Antitoxin IgG Blockade of Exotoxin Receptor Binding
consequence
Circulating neutralizing IgG antitoxin antibodies bind the receptor-binding (B) or translocation domains of secreted bacterial exotoxins in interstitial tissues and blood, sterically preventing toxin attachment to host cell-surface receptors (such as proHB-EGF for diphtheria toxin or neuronal gangliosides and synaptic receptors for tetanus neurotoxin) and arresting systemic toxin-driven disease while permitting asymptomatic mucosal carriage unless antibacterial immunity is also present.
Show evidence (4 references)
"We further established that our lead candidate hMAb binds to the receptor-binding domain of diphtheria toxin and physically blocks the toxin from binding to the putative receptor, heparin-binding epidermal growth factor-like growth factor."
Demonstrates the molecular mechanism of antitoxin IgG neutralization via steric blockade of the exotoxin receptor-binding domain.
"Most toxin neutralizing humAbs bind the HC receptor binding part of TeNT thus preventing binding (step 1), but one of them recognized domain HN preventing step 3)"
Shows that neutralizing human antibodies against tetanus neurotoxin similarly target the heavy-chain receptor-binding and translocation domains to prevent host cell entry.
"A large meta-analysis of clinical studies of diphtheria estimated that the receipt of three doses of diphtheria toxoid vaccine was 87% effective against symptomatic disease and reduced transmission by 60%."
Quantifies clinical protection against symptomatic toxin-mediated disease conferred by three-dose toxoid immunization.
+ 1 more reference